WallStreetZen

NYSEMKT: OCX
Oncocyte Corp Stock Forecast, Predictions & Price Target

Analyst price target for OCX

Based on 2 analysts offering 12 month price targets for Oncocyte Corp.
Min Forecast
$4.00+81.82%
Avg Forecast
$5.50+150%
Max Forecast
$7.00+218.18%

Should I buy or sell OCX stock?

Based on 2 analysts offering ratings for Oncocyte Corp.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

OCX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Needham
Top 31%
70
BuyMaintains$7.00+218.18%2021-11-10
Piper Sandler
Bottom 1%
1
Strong BuyUpgrades$4.00+81.82%2020-12-16

1 of 1

Forecast return on equity

Is OCX forecast to generate an efficient return?
Company
13%
Industry
21.88%
Market
37.5%
OCX's Return on Equity is forecast to be low in 3 years (13%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is OCX forecast to generate an efficient return on assets?
Company
7.67%
Industry
6.66%
OCX is forecast to generate higher Return on Assets (7.67%) than the US Biotechnology industry average (6.66%)
Forecast

OCX earnings per share forecast

What is OCX's earnings per share in the next 3 years based on estimates from 1 analysts?
Avg 1 year Forecast
-$0.29-30.95%
Avg 2 year Forecast
-$0.22-47.62%
Avg 3 year Forecast
-$0.08-80.95%

OCX revenue forecast

What is OCX's revenue in the next 3 years based on estimates from 1 analysts?
Avg 1 year Forecast
$11.0M+137.02%
Avg 2 year Forecast
$26.2M+464.53%
Avg 3 year Forecast
$45.0M+869.62%
OCX's revenue is forecast to grow at an exceptional rate of 112.29% per year
Forecast

OCX revenue growth forecast

How is OCX forecast to perform vs Biotechnology companies and vs the US market?
Company
112.29%
Industry
30.03%
Market
10.08%
OCX's revenues are forecast to grow faster (112.29% per year) than the US Biotechnology industry average (30.03%)
Forecast
OCX's revenues are forecast to grow faster (112.29% per year) than the US market average (10.08%)
Forecast

Oncocyte Corp Stock Forecast FAQ

Is Oncocyte Corp Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: OCX) stock is to Strong Buy OCX stock.

Out of 2 analysts, 1 (50%) are recommending OCX as a Strong Buy, 1 (50%) are recommending OCX as a Buy, 0 (0%) are recommending OCX as a Hold, 0 (0%) are recommending OCX as a Sell, and 0 (0%) are recommending OCX as a Strong Sell.

What is OCX's earnings growth forecast for 2021-2023?

(NYSEMKT: OCX) Oncocyte Corp's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Oncocyte Corp's earnings in 2021 is -$34,521,000.On average, 1 Wall Street analysts forecast OCX's earnings for 2021 to be $-26,747,117, with the lowest OCX earnings forecast at $-26,747,117, and the highest OCX earnings forecast at $-26,747,117. On average, 1 Wall Street analysts forecast OCX's earnings for 2022 to be $-20,290,916, with the lowest OCX earnings forecast at $-20,290,916, and the highest OCX earnings forecast at $-20,290,916.

In 2023, OCX is forecast to generate $-7,378,515 in earnings, with the lowest earnings forecast at $-7,378,515 and the highest earnings forecast at $-7,378,515.

What is OCX's revenue growth forecast for 2021-2023?

(NYSEMKT: OCX) Oncocyte Corp's forecast annual revenue growth rate of 112.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.03%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Oncocyte Corp's revenue in 2021 is $4,641,000.On average, 1 Wall Street analysts forecast OCX's revenue for 2021 to be $1,014,545,807, with the lowest OCX revenue forecast at $1,014,545,807, and the highest OCX revenue forecast at $1,014,545,807. On average, 1 Wall Street analysts forecast OCX's revenue for 2022 to be $2,416,463,649, with the lowest OCX revenue forecast at $2,416,463,649, and the highest OCX revenue forecast at $2,416,463,649.

In 2023, OCX is forecast to generate $4,150,414,665 in revenue, with the lowest revenue forecast at $4,150,414,665 and the highest revenue forecast at $4,150,414,665.

What is OCX's forecast return on assets (ROA) for 2021-2024?

(NYSEMKT: OCX) forecast ROA is 7.67%, which is higher than the forecast US Biotechnology industry average of 6.66%.

What is OCX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OCX price target, the average OCX price target is $5.50, with the highest OCX stock price forecast at $7.00 and the lowest OCX stock price forecast at $4.00.

On average, Wall Street analysts predict that Oncocyte Corp's share price could stay at $5.50 by Nov 10, 2022. The average Oncocyte Corp stock price prediction forecasts a potential downside of N/A from the current OCX share price of $2.20.

What is OCX's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSEMKT: OCX) Oncocyte Corp's current Earnings Per Share (EPS) is -$0.42. On average, analysts forecast that OCX's EPS will be $-0.29 for 2021, with the lowest EPS forecast at $-0.29, and the highest EPS forecast at $-0.29. On average, analysts forecast that OCX's EPS will be $-0.22 for 2022, with the lowest EPS forecast at $-0.22, and the highest EPS forecast at $-0.22. In 2023, OCX's EPS is forecast to hit $-0.08 (min: $-0.08, max: $-0.08).

What is OCX's forecast return on equity (ROE) for 2021-2024?

(NYSEMKT: OCX) forecast ROE is 13%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.